These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24827780)

  • 1. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 4. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
    Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract]   [Full Text] [Related]  

  • 6. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 7. Summary report of the First International Conference on inhibitors in haemophilia A.
    Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
    Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
    [No Abstract]   [Full Text] [Related]  

  • 8. Making clinical decisions on the basis of RODIN.
    Mannucci PM
    Haemophilia; 2014 Mar; 20(2):e174-5. PubMed ID: 24533956
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
    Zhang AH; Skupsky J; Scott DW
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):114-24. PubMed ID: 19199081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cluster of inhibitors among adult inpatients with haemophilia in a single institution.
    Ishaku NG; Key NS; Miller CH; Nielsen B; Buckner T; Chen SL; Hooper WC; Soucie JM
    Haemophilia; 2015 Jul; 21(4):e325-8. PubMed ID: 25939561
    [No Abstract]   [Full Text] [Related]  

  • 14. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
    Kessler CM; Iorio A
    Haemophilia; 2013 May; 19(3):351-4. PubMed ID: 23577743
    [No Abstract]   [Full Text] [Related]  

  • 15. Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization.
    Kruse-Jarres R
    Haemophilia; 2014 Sep; 20 Suppl 6():1. PubMed ID: 24975699
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
    van den Berg HM
    Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 18. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
    Scott DW; Pratt KP
    Front Immunol; 2019; 10():3078. PubMed ID: 32010137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.